
MAXSHOT.PL / Shutterstock.com
5 September 2025NewsAmericasMarisa Woutersen
GSK escalates mRNA COVID-19 vaccine dispute
The UK pharma giant has opened a new front in its global litigation strategy involving Moderna, Pfizer, and BioNTech.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
8 August 2025 Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.
Europe
4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
Americas
16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Editor's picks
Editor's picks
Americas
8 August 2025 Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.
Europe
4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
Americas
16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.
Americas
8 August 2025 Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.
Europe
4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
Americas
16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.